 |
 |
 |
 |
 |
 |
 |
 |
 |
scientific advisory board
- management team
- board of directors
- founders
- investors
- scientific advisors
- alliances
Dr. Ausiello is the Jackson Professor of Clinical Medicine at Harvard Medical School, Chief of Medicine at
Massachusetts General Hospital, and Chief Scientific Officer of Partners Healthcare. He received his undergraduate degree from Harvard College and his medical degree from the University of Pennsylvania.
He has made a substantial contribution to the knowledge of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction. He has published numerous articles, book chapters, and textbooks and currently serves as the co-editor of Cecil's Textbook of Medicine, now in its 23rd edition. A nationally recognized leader in academic medicine, Dr. Ausiello was elected to the Institute of Medicine of the National Academy of Science in 1999 and the American Academy of Arts and Sciences in 2003. Dr. Ausiello served as Chief of the MGH Renal Unit and oversaw its development into one of the most sought after research and training programs in the world.
As Chief of Medicine at MGH, a position he has held since 1996, he leads one of the strongest Departments of Medicine in the country with a clinical, research and education budget exceeding $600 million annually. He is closely involved with the Partners HealthCare System, linking the resources of the MGH, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute to provide comprehensive health care.
As an internationally recognized scientist, Dr. Ausiello has been the recipient of two MERIT awards from the National Institutes of Health and has served as a counsel member of th National Institute of Diabetes, Digestive and Kidney Diseases Advisory Council and the National Advisory Council on Aging.
Massachusetts General Hospital, and Chief Scientific Officer of Partners Healthcare. He received his undergraduate degree from Harvard College and his medical degree from the University of Pennsylvania. He has made a substantial contribution to the knowledge of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction. He has published numerous articles, book chapters, and textbooks and currently serves as the co-editor of Cecil's Textbook of Medicine, now in its 23rd edition. A nationally recognized leader in academic medicine, Dr. Ausiello was elected to the Institute of Medicine of the National Academy of Science in 1999 and the American Academy of Arts and Sciences in 2003. Dr. Ausiello served as Chief of the MGH Renal Unit and oversaw its development into one of the most sought after research and training programs in the world.
As Chief of Medicine at MGH, a position he has held since 1996, he leads one of the strongest Departments of Medicine in the country with a clinical, research and education budget exceeding $600 million annually. He is closely involved with the Partners HealthCare System, linking the resources of the MGH, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute to provide comprehensive health care.
As an internationally recognized scientist, Dr. Ausiello has been the recipient of two MERIT awards from the National Institutes of Health and has served as a counsel member of th National Institute of Diabetes, Digestive and Kidney Diseases Advisory Council and the National Advisory Council on Aging.
Professor Peter J. Barnes, FMedSci, FRS, is Professor of Thoracic Medicine and Head of Airway Disease at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London. He qualified at Cambridge and Oxford Universities was appointed to his present post in 1987. He has published over 1,000 peer-review papers on asthma, COPD and related topics and has edited over 40 books.
He is also amongst the top 50 most highly cited researchers in the world and has been the most highly cited clinical scientist in the UK and the most highly cited respiratory researcher in the world over the last 20 years. He was elected a Fellow of the Royal Society in 2007, the first respiratory researcher for over 150 years. He is currently a member of the Scientific Committee of the WHO/NIH global guidelines on asthma (GINA) and COPD (GOLD). He also serves on the Editorial Board of over 30 journals and is currently an Associate Editor of Chest and respiratory Editor of PLoS Medicine. He has given several prestigious lectures, including the Amberson Lecture at the American Thoracic Society and the Sadoul Lecture at the European Respiratory Society.
His research is focused on cellular and molecular mechanisms of asthma and COPD, understanding and developing therapies and research into biomarkers for these diseases. He is involved in multidisciplinary translational research which integrates basic science with clinical studies, thereby providing novel insights into common airway diseases.
Airway Disease at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London. He qualified at Cambridge and Oxford Universities was appointed to his present post in 1987. He has published over 1,000 peer-review papers on asthma, COPD and related topics and has edited over 40 books.He is also amongst the top 50 most highly cited researchers in the world and has been the most highly cited clinical scientist in the UK and the most highly cited respiratory researcher in the world over the last 20 years. He was elected a Fellow of the Royal Society in 2007, the first respiratory researcher for over 150 years. He is currently a member of the Scientific Committee of the WHO/NIH global guidelines on asthma (GINA) and COPD (GOLD). He also serves on the Editorial Board of over 30 journals and is currently an Associate Editor of Chest and respiratory Editor of PLoS Medicine. He has given several prestigious lectures, including the Amberson Lecture at the American Thoracic Society and the Sadoul Lecture at the European Respiratory Society.
His research is focused on cellular and molecular mechanisms of asthma and COPD, understanding and developing therapies and research into biomarkers for these diseases. He is involved in multidisciplinary translational research which integrates basic science with clinical studies, thereby providing novel insights into common airway diseases.
Dr. Boucher has extensive experience in the study of the pathophysiology and therapy of chronic airways diseases, including cystic fibrosis. He is currently a William Rand Kenan Professor of Medicine at the University of North Carolina, the Chief of Pulmonary Medicine, Director of the UNC Cystic Fibrosis/Pulmonary Research and Treatment Center, and Co-Director of the UNC Gene Therapy Center. He has published more than 400 papers on all aspects of pulmonary medicine and cystic fibrosis. In addition, Dr. Boucher was a founder of Inspire Pharmaceuticals, a biotechnology company focused on developing novel nucleotide-based therapies for the treatment of lung disease.
Dr. Boucher is Co-Founder & Chairman of the Board of Parion, a privately held development-stage pharmaceutical company focused on the discovery and development of new treatments for pulmonary indications including cystic fibrosis, COPD, and bronchiectasis. He holds more than 30 patents focused on novel therapies of lung diseases. He received his BA from Yale University and his MD from Columbia University.
diseases, including cystic fibrosis. He is currently a William Rand Kenan Professor of Medicine at the University of North Carolina, the Chief of Pulmonary Medicine, Director of the UNC Cystic Fibrosis/Pulmonary Research and Treatment Center, and Co-Director of the UNC Gene Therapy Center. He has published more than 400 papers on all aspects of pulmonary medicine and cystic fibrosis. In addition, Dr. Boucher was a founder of Inspire Pharmaceuticals, a biotechnology company focused on developing novel nucleotide-based therapies for the treatment of lung disease.Dr. Boucher is Co-Founder & Chairman of the Board of Parion, a privately held development-stage pharmaceutical company focused on the discovery and development of new treatments for pulmonary indications including cystic fibrosis, COPD, and bronchiectasis. He holds more than 30 patents focused on novel therapies of lung diseases. He received his BA from Yale University and his MD from Columbia University.
Dr. Calderwood, an infectious diseases specialist and Chief of the Infectious Disease (ID) Division at Massachusetts General Hospital, graduated from Harvard College and Harvard Medical School. He trained in medicine and ID at MGH, where he was chief resident in medicine. He is co-chair of the Training Council, Promotions Committee, and Medical Services a MGH. He teaches in the microbiology courses of both Harvard and New Pathway, as well as the ABS course, Modern Medical Microbe Hunters. He is Co-Editor-in-Chief of UpToDate, Infectious Diseases section.
Massachusetts General Hospital, graduated from Harvard College and Harvard Medical School. He trained in medicine and ID at MGH, where he was chief resident in medicine. He is co-chair of the Training Council, Promotions Committee, and Medical Services a MGH. He teaches in the microbiology courses of both Harvard and New Pathway, as well as the ABS course, Modern Medical Microbe Hunters. He is Co-Editor-in-Chief of UpToDate, Infectious Diseases section.
Dr. Clapham is a leader in cell signal transduction, with particular expertise in ion channels andG protein-coupled receptors. As the Aldo R. Casteñada Professor of Cardiovascular Research at Children's Hospital of Boston, he is the hospital's director of Cardiovascular Research. He is also a professor of Neurobiology a Harvard Medical School, and a member of the American Academy of Arts and Sciences and the National Academy of Sciences.
Early in his career, David established his independent research laboratory in the Department of Medicine at Brigham and Women's Hospital of HMS. He earned an MD and PhD in Anatomy/Cell Biology from Emory University School of Medicine and an Electrical Engineering degree at the Georgia Institute of Technology. David was a senior Fulbright Fellow during his postdoctoral training with Erwin Neher at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. Dr. Neher is the co-inventor (with B. Sakmann) of the patch clamp technique for which he won a Nobel Prize.
G protein-coupled receptors. As the Aldo R. Casteñada Professor of Cardiovascular Research at Children's Hospital of Boston, he is the hospital's director of Cardiovascular Research. He is also a professor of Neurobiology a Harvard Medical School, and a member of the American Academy of Arts and Sciences and the National Academy of Sciences. Early in his career, David established his independent research laboratory in the Department of Medicine at Brigham and Women's Hospital of HMS. He earned an MD and PhD in Anatomy/Cell Biology from Emory University School of Medicine and an Electrical Engineering degree at the Georgia Institute of Technology. David was a senior Fulbright Fellow during his postdoctoral training with Erwin Neher at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. Dr. Neher is the co-inventor (with B. Sakmann) of the patch clamp technique for which he won a Nobel Prize.
Dr. Edwards is the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University, where his work focuses on the fields of fluid mechanics, interfacial transport phenomena, drug delivery, and aerosol science. His current research is supported by grants from the National Institutes of Health and the Bill and Melinda Gates Foundation, and includes the investigation of the fluid mechanical properties of the lung lining fluid that permit control of expired bioaerosol and mitigation of the spread of inhaled infectious disease, the development of novel antibiotic therapies for tuberculosis, and a new delivery platform for needleless childhood vaccines.
Dr. Edwards has published over 70 papers on the aerosol delivery of macromolecules to the lung and a variety of related subjects. He is a Fellow of the American Institute of Medical and Biological Engineering and a Member of the National Academy of Engineering. Dr. Edwards is a recipient of numerous awards including the Professional Progress Award of the American Institute of Chemical Engineers, and is a three time recipient of the Ebert Prize of the American Pharmaceutical Association.
He is a member of the Advisory Board at the Center for Civilian Biodefense Strategies at the Johns Hopkins University. He is also the founder of Advanced Inhalation Research (AIR) which was acquired by Alkermes, Inc., and Chairman of the Board of the international not-for-profit Medicine in Need (MEND).
University, where his work focuses on the fields of fluid mechanics, interfacial transport phenomena, drug delivery, and aerosol science. His current research is supported by grants from the National Institutes of Health and the Bill and Melinda Gates Foundation, and includes the investigation of the fluid mechanical properties of the lung lining fluid that permit control of expired bioaerosol and mitigation of the spread of inhaled infectious disease, the development of novel antibiotic therapies for tuberculosis, and a new delivery platform for needleless childhood vaccines. Dr. Edwards has published over 70 papers on the aerosol delivery of macromolecules to the lung and a variety of related subjects. He is a Fellow of the American Institute of Medical and Biological Engineering and a Member of the National Academy of Engineering. Dr. Edwards is a recipient of numerous awards including the Professional Progress Award of the American Institute of Chemical Engineers, and is a three time recipient of the Ebert Prize of the American Pharmaceutical Association.
He is a member of the Advisory Board at the Center for Civilian Biodefense Strategies at the Johns Hopkins University. He is also the founder of Advanced Inhalation Research (AIR) which was acquired by Alkermes, Inc., and Chairman of the Board of the international not-for-profit Medicine in Need (MEND).
Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. In this position she has had oversight for two Phase II and 3 Phase I studies and has built up a network of leading clinical respiratory consultants including Professor Neil Barnes, Dr Dave Singh and Professor Peter Calverley. Considered one of the world leaders in drug development for COPD and in the preclinical models for respiratory disease, Dr. Fitzgerald has been a Director of Argenta/Pulmagen since October 2004. She has been responsible for clinical development at Argenta and more recently at Pulmagen Therapeutics since 2008. Since 2002, she has also been Director of and is a founding member of Etiologics Limited.
Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She has spent over 20 years conducting research into chronic respiratory disease. She was the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease.
where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. In this position she has had oversight for two Phase II and 3 Phase I studies and has built up a network of leading clinical respiratory consultants including Professor Neil Barnes, Dr Dave Singh and Professor Peter Calverley. Considered one of the world leaders in drug development for COPD and in the preclinical models for respiratory disease, Dr. Fitzgerald has been a Director of Argenta/Pulmagen since October 2004. She has been responsible for clinical development at Argenta and more recently at Pulmagen Therapeutics since 2008. Since 2002, she has also been Director of and is a founding member of Etiologics Limited.Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She has spent over 20 years conducting research into chronic respiratory disease. She was the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease.
Professor Tony Hickey, PhD, is Professor Emeritus of Molecular Pharmaceutics of the School of Pharmacy, and Biomedical Engineering of the School of Medicine, at the University of North Carolina at Chapel Hill. He obtained PhD (1984) and DSc (2003) degrees in pharmaceutical sciences from Aston University, Birmingham, UK, following postdoctoral positions, at the University of Kentucky (1984-1988).
Dr. Hickey is founder, President and CEO of Cirrus Pharmaceuticals, Inc. (since 1997), founder (2001, and formerly CSO, 2002-2007) of Oriel Therapeutics, Inc. (acquired by Sandoz Inc. 2010), past Chair of the Aerosols Expert Committee of the United States Pharmacopeia (2005-2010), current member of the Pharmaceutical Dosage Forms Expert Committee (2010-2015) and Program Director for Innovation and Translation Alliances of the not-for-profit, Medicine in Need (since 2009). Dr. Hickey leads a multidisciplinary research group in the field of pulmonary drug and vaccine delivery.
Pharmacy, and Biomedical Engineering of the School of Medicine, at the University of North Carolina at Chapel Hill. He obtained PhD (1984) and DSc (2003) degrees in pharmaceutical sciences from Aston University, Birmingham, UK, following postdoctoral positions, at the University of Kentucky (1984-1988).Dr. Hickey is founder, President and CEO of Cirrus Pharmaceuticals, Inc. (since 1997), founder (2001, and formerly CSO, 2002-2007) of Oriel Therapeutics, Inc. (acquired by Sandoz Inc. 2010), past Chair of the Aerosols Expert Committee of the United States Pharmacopeia (2005-2010), current member of the Pharmaceutical Dosage Forms Expert Committee (2010-2015) and Program Director for Innovation and Translation Alliances of the not-for-profit, Medicine in Need (since 2009). Dr. Hickey leads a multidisciplinary research group in the field of pulmonary drug and vaccine delivery.
Dr. Langer is the Kenneth J. Germeshausen Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology. The only active member of all three U.S. National Academies (the National Academy of Sciences, the Institute of Medicine, and the National Academy of Engineering), Dr. Langer is one of 14 Institute Professors at MIT. His career has focused on pioneering work at the interface of biotechnology, drug delivery, and materials science, resulting in over 1000 articles and over 600 issued or pending patents worldwide. His patents have further been licensed or sublicensed to over 200 pharmaceutical, chemical, biotechnology, and medical device companies.
Dr. Langer is a founder of over 20 successful companies, including Momenta, Alnylam, Transform Pharmaceuticals, Pervasis, and Advanced Inhalation Research (AIR). Dr. Langer has additionally served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 to 2002, and as its Chairman from 1999 to 2002.
Dr. Langer has received over 160 major awards including the 2006 United States National Medal of Science, the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, and the 2008 Millennium Prize, the world’s largest technology prize. Dr. Langer received his BS from Cornell University, and his ScD from the MIT, both in Chemical Engineering.
Massachusetts Institute of Technology. The only active member of all three U.S. National Academies (the National Academy of Sciences, the Institute of Medicine, and the National Academy of Engineering), Dr. Langer is one of 14 Institute Professors at MIT. His career has focused on pioneering work at the interface of biotechnology, drug delivery, and materials science, resulting in over 1000 articles and over 600 issued or pending patents worldwide. His patents have further been licensed or sublicensed to over 200 pharmaceutical, chemical, biotechnology, and medical device companies.Dr. Langer is a founder of over 20 successful companies, including Momenta, Alnylam, Transform Pharmaceuticals, Pervasis, and Advanced Inhalation Research (AIR). Dr. Langer has additionally served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 to 2002, and as its Chairman from 1999 to 2002.
Dr. Langer has received over 160 major awards including the 2006 United States National Medal of Science, the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, and the 2008 Millennium Prize, the world’s largest technology prize. Dr. Langer received his BS from Cornell University, and his ScD from the MIT, both in Chemical Engineering.
Dr. Palese is Professor of Microbiology and Chair of the Department of Microbiology at the Mount Sinai School of Medicine in New York. He has over 270 scientific publications that include research on the replication of RNA-containing viruses with a special emphasis on influenza viruses, which are negative-strand RNA viruses. Specifically, he established the first genetic maps for influenza A, B and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals.
Dr. Palese also pioneered the field of reverse genetics for negative strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses Dr. Palese was elected to the National Academy of Sciences in 2000 for his seminal studies on influenza viruses. At present he serves on the editorial board for the Proceedings of the National Academy of Sciences and as an editor for the Journal of Virology.
Dr. Palese was president of the Harvey Society in 2004, president of the American Society for Virology in 2005 and he was a recipient of the Robert Koch Prize in 2006 and of the Charles C. Shepard Science Award in 2008.
School of Medicine in New York. He has over 270 scientific publications that include research on the replication of RNA-containing viruses with a special emphasis on influenza viruses, which are negative-strand RNA viruses. Specifically, he established the first genetic maps for influenza A, B and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals.Dr. Palese also pioneered the field of reverse genetics for negative strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses Dr. Palese was elected to the National Academy of Sciences in 2000 for his seminal studies on influenza viruses. At present he serves on the editorial board for the Proceedings of the National Academy of Sciences and as an editor for the Journal of Virology.
Dr. Palese was president of the Harvey Society in 2004, president of the American Society for Virology in 2005 and he was a recipient of the Robert Koch Prize in 2006 and of the Charles C. Shepard Science Award in 2008.
Professor Sanjay Sethi, MD, is Chief, Division of Pulmonary, Critical Care and Sleep Medicine, in the Department of Medicine at the University of Buffalo at the State University of New York (SUNY) where he also completed a fellowship in pulmonary and critical care medicine. He is the Chief of the Division of Pulmonary/Critical Care/Sleep Medicine at the University at Buffalo and the Section Chief for Pulmonary/Critical Care/Sleep Medicine at the Western New York Veterans Administration HealthCare System in Buffalo.
Dr. Sethi completed his internship and residency in internal medicine at Cook County Hospital in Chicago, Illinois and is board certified in internal medicine, pulmonary disease, and critical care medicine. Dr. Sethi’s main research interests include respiratory infections and chronic obstructive pulmonary disease, focused on the specific areas of bacterial infection in COPD, epidemiology and clinical implications of antimicrobial resistance and innate lung defense in COPD. Dr. Sethi’s has co-authored more than a 100 research articles and reviews in many peer-reviewed medical journals including New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine, Chest, COPD: Journal of Chronic Obstructive Pulmonary Disease, Infection and Immunity, Journal of Infectious Diseases, and Journal of Antimicrobial Chemotherapy.
Sleep Medicine, in the Department of Medicine at the University of Buffalo at the State University of New York (SUNY) where he also completed a fellowship in pulmonary and critical care medicine. He is the Chief of the Division of Pulmonary/Critical Care/Sleep Medicine at the University at Buffalo and the Section Chief for Pulmonary/Critical Care/Sleep Medicine at the Western New York Veterans Administration HealthCare System in Buffalo.Dr. Sethi completed his internship and residency in internal medicine at Cook County Hospital in Chicago, Illinois and is board certified in internal medicine, pulmonary disease, and critical care medicine. Dr. Sethi’s main research interests include respiratory infections and chronic obstructive pulmonary disease, focused on the specific areas of bacterial infection in COPD, epidemiology and clinical implications of antimicrobial resistance and innate lung defense in COPD. Dr. Sethi’s has co-authored more than a 100 research articles and reviews in many peer-reviewed medical journals including New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine, Chest, COPD: Journal of Chronic Obstructive Pulmonary Disease, Infection and Immunity, Journal of Infectious Diseases, and Journal of Antimicrobial Chemotherapy.
Dr. Ulevitch joined 5AM Ventures as Venture Partner in February 2008. Prior to this date, he was Chairman of the 5AM Scientific Advisory Board while serving as Professor and Chairman of the Department of Immunology at The Scripps Research Institute, La Jolla, California. He remains as Chairman Emeritus at The Scripps Research Institute.
For nearly three decades, Dr. Ulevitch has performed research to understand the role of the immune system in human disease. He also serves as a scientific advisor to European life science venture capital fund, Aravis Ventures, and was previously an advisor to the Lombard Odier Immunology Fund, and has evaluated hundreds of biotechnology companies over the past fifteen years. Dr. Ulevitch received an A.B. from Washington and Jefferson College and a PhD in Biochemistry from the University of Pennsylvania.
of the 5AM Scientific Advisory Board while serving as Professor and Chairman of the Department of Immunology at The Scripps Research Institute, La Jolla, California. He remains as Chairman Emeritus at The Scripps Research Institute.For nearly three decades, Dr. Ulevitch has performed research to understand the role of the immune system in human disease. He also serves as a scientific advisor to European life science venture capital fund, Aravis Ventures, and was previously an advisor to the Lombard Odier Immunology Fund, and has evaluated hundreds of biotechnology companies over the past fifteen years. Dr. Ulevitch received an A.B. from Washington and Jefferson College and a PhD in Biochemistry from the University of Pennsylvania.
Professor Charles R. Wira, PhD, is Professor of Physiology and Neurobiology at Dartmouth Medical School. Dr. Wira’s research focuses on how hormones influence immunity. Dr. Wira has been funded by NIH for the past 35 years, has published approximately 160 research papers, and serves as editor on several scientific journals. He has received numerous awards including a National Institutes of Health Merit Award, which is awarded to approximately 0.1% of scientists by NIH. He is also the recipient of the Distinguished Investigator Award in Reproductive Immunology by the American Society of reproductive Immunology (ASRI). As Principal Investigator of an NIH funded Program Project grants for the past 14 years, he heads a major collaborative effort at Dartmouth Medical School to characterize immune functions in the Fallopian tube, uterus, cervix and vagina and to define the roles of sex hormones in mucosal immune regulation.
Dr. Wira received his B.S. in 1962 in Animal Husbandry from Delaware Valley College, Doylestown, PA and his M.S. in Physiology from Michigan State University in 1966. Dr. Wira came to Dartmouth in 1966 where he received his Ph.D. in 1970. From 1970 to 1972 he did his postdoctoral training at the University of Paris, France, studying molecular mechanism of estrogen action in the uterus. He returned to Dartmouth as an Assistant Professor in the Department of Physiology and was promoted to Professor in 1985.
School. Dr. Wira’s research focuses on how hormones influence immunity. Dr. Wira has been funded by NIH for the past 35 years, has published approximately 160 research papers, and serves as editor on several scientific journals. He has received numerous awards including a National Institutes of Health Merit Award, which is awarded to approximately 0.1% of scientists by NIH. He is also the recipient of the Distinguished Investigator Award in Reproductive Immunology by the American Society of reproductive Immunology (ASRI). As Principal Investigator of an NIH funded Program Project grants for the past 14 years, he heads a major collaborative effort at Dartmouth Medical School to characterize immune functions in the Fallopian tube, uterus, cervix and vagina and to define the roles of sex hormones in mucosal immune regulation.Dr. Wira received his B.S. in 1962 in Animal Husbandry from Delaware Valley College, Doylestown, PA and his M.S. in Physiology from Michigan State University in 1966. Dr. Wira came to Dartmouth in 1966 where he received his Ph.D. in 1970. From 1970 to 1972 he did his postdoctoral training at the University of Paris, France, studying molecular mechanism of estrogen action in the uterus. He returned to Dartmouth as an Assistant Professor in the Department of Physiology and was promoted to Professor in 1985.
Michael Yeadon, PhD, is a world-renowned expert in allergy and respiratory diseases, with over 23 years of experience in drug discovery and development. He was most recently Vice President and Chief Scientific Officer of the Allergy and Respiratory Unit of Pfizer. At Pfizer, he led the creation of one of the industry’s leading allergy and respiratory portfolios, crafting a compelling strategy for the Allergy and Respiratory business, leveraging linkages between indications and exploiting inflammation and inhalation capabilities of Pfizer. He joined Pfizer in 1995 and held a series of research and development (R&D) roles of increasing responsibility. Prior to Pfizer, Dr. Yeadon was a team leader at Wellcome Research Labs, having joined as a new post-graduate in 1988. He attended the University of Surrey in Guildford, U.K, where received his PhD, with thesis work in the respiratory field, and a BSc, First Class, with Joint Honours, in Biochemistry and Toxicology.
of experience in drug discovery and development. He was most recently Vice President and Chief Scientific Officer of the Allergy and Respiratory Unit of Pfizer. At Pfizer, he led the creation of one of the industry’s leading allergy and respiratory portfolios, crafting a compelling strategy for the Allergy and Respiratory business, leveraging linkages between indications and exploiting inflammation and inhalation capabilities of Pfizer. He joined Pfizer in 1995 and held a series of research and development (R&D) roles of increasing responsibility. Prior to Pfizer, Dr. Yeadon was a team leader at Wellcome Research Labs, having joined as a new post-graduate in 1988. He attended the University of Surrey in Guildford, U.K, where received his PhD, with thesis work in the respiratory field, and a BSc, First Class, with Joint Honours, in Biochemistry and Toxicology.
© 2011 Pulmatrix, Inc. All Rights Reserved
home about pulmatrix science pipeline applications publications news careers contact site design
home about pulmatrix science pipeline applications publications news careers contact site design